Is Camlin Fine Sciences a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Camlin Fine Sciences Ltd is a below average quality company .

Is Camlin Fine Sciences undervalued or overvalued?

The key valuation ratios of Camlin Fine Sciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Camlin Fine Sciences share price return in the past 10 years?

Camlin Fine Sciences Ltd share price has appreciated 9.8% annually (CAGR) over the past ten years.

Is Camlin Fine Sciences a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Camlin Fine Sciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Camlin Fine Sciences Ltd - Stock Valuation and Financial Performance

Name: Camlin Fine Sciences
Brand: Camlin Fine Sciences

BSE: 532834 | NSE: CAMLINFINE | Chemicals | Small Cap

Place order

Camlin Fine Sciences Share Price

₹121.50 4.85 4.16%
as on 26-Jul'24 16:01

10 Year X-Ray of Camlin Fine Sciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	18.8%	16.8%	5.7%	0.5%	4.1%	6.1%	5.3%	4.8%	6.5%	-0.8%	-
Value Creation Index ⓘ	0.3	0.2	-0.6	-1.0	-0.7	-0.6	-0.6	-0.7	-0.5	-1.1	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	431	412	325	403	548	580	600	686	789	773	773
Sales YoY Gr.	-	-4.3%	-21.2%	24.1%	36.1%	5.8%	3.5%	14.2%	15.2%	-2.1%	-
Adj EPS ⓘ	2.8	2.9	0.2	-1.3	0.7	1.7	1.1	1.2	2	-3.2	-3.1
YoY Gr.	-	3.2%	-93.7%	-833.3%	NA	130.6%	-31.9%	9.7%	59.7%	-261.6%	-
BVPS (₹) ⓘ	10.2	12.5	16.8	25.5	26.8	31	32.4	37	40	41.9	41.9
Adj Net Profit ⓘ	26.6	27.7	1.9	-16.1	8.8	20.2	14.4	19.4	31.1	-53.6	-51
Cash Flow from Ops. ⓘ	26.4	50.9	-30.1	-5.2	-44.6	73.9	26	46.8	18.5	82.1	-
Debt/CF from Ops. ⓘ	5.1	3.1	-8.1	-41.7	-7	4.5	14.3	9.6	32.6	6	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	6.7%	7.1%	8.8%	-2.1%
Adj EPS ⓘ	-201.6%	-234.8%	-241.5%	-261.6%
BVPSⓘ	17%	9.3%	8.9%	4.8%
Share Price	9.8%	17.5%	-14.3%	-22.9%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	30.5	25.4	1.3	-6.3	2.6	5.6	3.4	3.7	5	-7.9	-7.3
Op. Profit Mgn % ⓘ	14.5	16.5	8.5	1.1	6	10.4	12.4	11.6	16.8	4.3	3.5
Net Profit Mgn % ⓘ	6.2	6.7	0.6	-4	1.6	3.5	2.4	2.8	3.9	-6.9	-6.7
Debt to Equity ⓘ	1.4	1.3	1.4	0.7	1	0.9	0.9	0.8	1	0.7	0.3
Working Cap Days ⓘ	200	232	322	338	305	315	338	344	366	415	182
Cash Conv. Cycle ⓘ	68	96	181	180	152	162	168	165	193	233	60

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.70

Return on Equity is Poor

Sales growth has been subdued in last 3 years 8.82%

Sales growth is not so good in last 4 quarters at -0.77%

Latest Financials - Camlin Fine Sciences Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-3.1	-5.5
TTM Sales (₹ Cr.)	773	1,613
BVPS (₹.) ⓘ	41.9	48.1
Reserves (₹ Cr.) ⓘ	685	789
P/BV ⓘ	2.88	2.51
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	80.00 / 186.25
All Time Low / High (₹)	1.94 / 230.80
Market Cap (₹ Cr.)	2,023
Equity (₹ Cr.)	16.8
Face Value (₹)	1
Industry PE ⓘ	56.8

Management X-Ray of Camlin Fine Sciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

12.43

* Pledged shares as % of Promoter's holding (%)

Valuation of Camlin Fine Sciences

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Camlin Fine Sciences

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	431	412	325	403	548	580	600	686	789	773
Operating Expenses ⓘ	370	345	301	399	515	519	534	606	657	741
Manufacturing Costs	33	37	29	34	42	50	64	96	157	169
Material Costs	279	244	204	303	409	389	378	395	366	444
Employee Cost	18	19	22	21	23	28	39	53	60	66
Other Costs ⓘ	41	44	47	41	42	52	54	63	75	62
Operating Profit ⓘ	61	68	23	4	33	60	66	79	132	33
Operating Profit Margin (%)	14.1%	16.4%	7.2%	1.0%	6.0%	10.4%	10.9%	11.6%	16.8%	4.2%
Other Income ⓘ	2	4	14	13	14	27	8	20	29	21
Interest ⓘ	21	22	26	26	23	31	38	36	62	62
Depreciation ⓘ	10	10	12	9	9	11	19	27	33	49
Exceptional Items ⓘ	0	-5	0	0	0	-3	-1	0	0	-2
Profit Before Tax ⓘ	32	35	0	-18	14	41	15	36	67	-60
Tax ⓘ	6	9	1	-4	3	11	7	10	19	-8
Profit After Tax	26	26	-1	-14	11	31	8	26	48	-51
PAT Margin (%)	6.0%	6.2%	-0.2%	-3.5%	2.0%	5.3%	1.4%	3.8%	6.0%	-6.6%
Adjusted EPS (₹)	2.7	2.7	-0.1	-1.2	0.9	2.5	0.7	1.7	3.0	-3.1
Dividend Payout Ratio (%)	17%	17%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	98	121	174	309	325	376	413	580	628	702
Share Capital ⓘ	10	10	10	12	12	12	13	16	16	17
Reserves ⓘ	88	111	164	297	313	364	400	564	612	685
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	124	146	234	215	310	331	363	438	512	456
Long Term Debt	27	20	11	14	111	113	163	258	292	222
Short Term Debt	98	126	223	200	199	218	201	180	220	233
Trade Payables	94	80	36	114	106	133	193	212	249	284
Others Liabilities ⓘ	30	36	29	38	39	51	97	116	205	130
Total Liabilities ⓘ	346	382	474	676	780	891	1,067	1,346	1,594	1,572
Fixed Assets
Gross Block	124	160	88	90	109	131	348	381	682	723
Accumulated Depreciation	61	71	11	20	29	37	56	77	99	147
Net Fixed Assetsⓘ	63	89	76	70	80	94	292	304	583	577
CWIP ⓘ	0	1	14	20	68	198	18	207	28	31
Investmentsⓘ	5	7	44	148	69	74	74	82	82	80
Inventories	90	118	116	115	109	97	131	142	252	255
Trade Receivables	124	98	131	211	262	323	368	441	526	492
Cash Equivalents	12	13	13	11	69	13	82	56	10	14
Others Assetsⓘ	52	55	78	101	122	92	102	113	113	123
Total Assets ⓘ	346	382	474	676	780	891	1,067	1,346	1,594	1,572

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	26	51	-30	-5	-45	74	26	47	19	82
PBT ⓘ	32	35	0	-18	14	41	15	36	67	-60
Adjustment ⓘ	30	33	29	19	19	22	65	55	76	140
Changes in Working Capital ⓘ	-25	-11	-52	-6	-74	12	-44	-43	-117	20
Tax Paid ⓘ	-10	-6	-7	0	-4	-1	-10	-1	-7	-18
Cash Flow From Investing Activity ⓘ	-23	-49	-31	-116	-3	-66	-88	-172	-115	-52
Capex	-23	-37	-6	-15	-52	-115	-39	-189	-131	-41
Net Investments	-1	-2	-26	-102	43	44	-50	28	29	-8
Others ⓘ	1	-10	2	1	5	5	2	-11	-12	-3
Cash Flow From Financing Activityⓘ	-5	-1	61	120	65	-26	80	129	78	-34
Net Proceeds from Shares ⓘ	1	3	58	148	0	0	0	1	1	1
Net Proceeds from Borrowing ⓘ	0	0	-14	-2	-10	-2	46	88	91	-1
Interest Paid ⓘ	-22	-22	-23	-24	-31	-39	-40	-31	-39	-47
Dividend Paid ⓘ	-3	-4	-5	0	0	0	0	0	0	0
Others ⓘ	19	22	45	-2	106	16	74	71	26	13
Net Cash Flow ⓘ	-1	0	0	-1	17	-18	18	3	-18	-4

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	29.67	23.55	-0.54	-5.87	3.38	8.76	2.1	5.21	7.87	-7.73
ROCE (%)	23.99	22.04	7.36	1.65	6.19	10.59	6.9	7.72	11.28	0.18
Asset Turnover Ratio	1.4	1.16	0.79	0.7	0.75	0.69	0.61	0.57	0.54	0.49
PAT to CFO Conversion(x)	1	1.96	N/A	N/A	-4.09	2.39	3.25	1.81	0.4	N/A
Working Capital Days
Receivable Days	89	96	124	154	158	184	210	215	224	240
Inventory Days	57	90	127	104	75	65	70	73	91	120
Payable Days	101	129	104	91	98	112	157	187	230	219

Camlin Fine Sciences Ltd Stock News

Camlin Fine Sciences Ltd FAQs

What is the share price of Camlin Fine Sciences?

Company share prices are keep on changing according to the market conditions. The closing price of Camlin Fine Sciences on 26-Jul-2024 16:01 is ₹121.5.

What is the market cap of Camlin Fine Sciences?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 26-Jul-2024 16:01 the market cap of Camlin Fine Sciences stood at ₹2,023.3.

What is the P/E ratio of Camlin Fine Sciences?

The latest P/E ratio of Camlin Fine Sciences as of 26-Jul-2024 16:01 is 0.00.

What is the P/B ratio of Camlin Fine Sciences?

The latest P/B ratio of Camlin Fine Sciences as of 26-Jul-2024 16:01 is 2.88.

What is the 52-week high and low of Camlin Fine Sciences?

The 52-week high of Camlin Fine Sciences is ₹186.2 and the 52-week low is ₹80.00.

What is the TTM revenue of Camlin Fine Sciences?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Camlin Fine Sciences is ₹773.3 ( Cr.) .

About Camlin Fine Sciences Ltd

Camlin, the corporate group, was established in 1931 and is a pioneer in art and stationery material in India. Camlin diversified into Pharmaceuticals and Fine Chemicals two decades ago. The Fine Chemical Division of Camlin got de-merged into a separate company named as Camlin Fine Chemicals on 22nd December 2006. The entire management team and employees of Camlin Fine Chemicals Division are now a part of the independent legal entity formed under the Indian Companies Act 1956. In 2011
Company changed its name from Camlin Fine Chemicals Ltd. to Camlin Fine Sciences Ltd.

Camlin Fine Chemicals is the world's second largest manufacturer and marketer of food grade antioxidants TBHQ and BHA. Its mission is to be the largest food antioxidant and ingredient manufacturer worldwide. Their facilities are HACCP and ISO 9001 : 2000 certified.

Product Range:

a) Food Ingredients â€“

Antox TBHQ (HACCP Certified) FCC V / FAO / WHO (Tertiary Butyl Hydroquinone)

Antox BHA (HACCP Certified) FCC V / FAO / WHO / EEC ( Butyl Hydroxy Anisole)

b) Sweetener -

Sucralose FCC V

c) Active Pharmaceutical Ingredients -

Miconazole Nitrate B.P. / USP
Clotrimazole B.P. / USP
Amlodipine Besilate E.P
Amlodipine Salts
Advance intermediate of Amlodipine
Intermediate of Miconazole Nitrate

d) Super Absorbent Polymer

Subsidiary Details:

Chemolutions Chemicals: Specialty Chemical Intermediates
Sangam Laboratories: Nutraceuticals
Fine Renewable Energy.
Fine LifeStyle Brands: Luxury Fashion Brands

On 6^th June 2008 - The company entered into a joint venture, on 51:49 basis, with US based Viachem LLC, to set up a joint venture company under the name Dulcette Technologies for marketing Sucralose, Aspartame, and Acesulfame-K, and their belnds in USA, Canada, and Maxico.

On 7^th July 2008 - The Board of Directors of the company at its meeting held on 29th July 2008, approved the proposal for setting up a joint venture company with Pagoda Advisors and their associates.

As per the deal, Camlin Fine Chemicals will get 51% of the equity of the proposed new company and the rest 49% will be owned by Pagoda Advisors and their associates.The proposed new company will focus on the retail of luxury/premium brands in India by setting up stores in all stores in all major metros and cities in India by itself and through franchisees.

On 25^th February 2008: Camlin Fine Chemicals acquired 60% equity stake in Sangam Laboratories, a Small Scale Unit manufacturing Nutraceuticals and Drug Intermediates at Tarapur.

On 12^th February 2008 - The company inked a joint venture deal with US based Advanced Aerospace Technologies to manufacture and market speciality fine chemicals primarily to cater to European and U.S markets.